Terms: = Breast cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2
36 results:
1. Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22-13).
Jang BS; Chun SJ; Choi HS; Chang JH; Shin KH;
Comput Methods Programs Biomed; 2024 Mar; 245():108049. PubMed ID: 38295597
[TBL] [Abstract] [Full Text] [Related]
2. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
Gao H; Ouyang D; Guan X; Xu J; Chen Q; Zeng L; Pang J; Zou Q; Qian K; Yi W
BMC Cancer; 2024 Jan; 24(1):50. PubMed ID: 38195475
[TBL] [Abstract] [Full Text] [Related]
3. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Mayer EL; Tayob N; Ren S; Savoie JJ; Spigel DR; Burris HA; Ryan PD; Harris LN; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2024 Feb; 204(1):123-132. PubMed ID: 38019444
[TBL] [Abstract] [Full Text] [Related]
4. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract] [Full Text] [Related]
5. Development and validation of genome-wide polygenic risk scores for predicting breast cancer incidence in Japanese females: a population-based case-cohort study.
Ohbe H; Hachiya T; Yamaji T; Nakano S; Miyamoto Y; Sutoh Y; Otsuka-Yamasaki Y; Shimizu A; Yasunaga H; Sawada N; Inoue M; Tsugane S; Iwasaki M;
Breast Cancer Res Treat; 2023 Feb; 197(3):661-671. PubMed ID: 36538246
[TBL] [Abstract] [Full Text] [Related]
6. Direct cd32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Sconocchia G; Lanzilli G; Cesarini V; Silvestris DA; Rezvani K; Arriga R; Caratelli S; Chen K; Dou J; Cenciarelli C; Toietta G; Baldari S; Sconocchia T; De Paolis F; Aureli A; Iezzi G; Irno Consalvo M; Buccisano F; Del Principe MI; Maurillo L; Venditti A; Ottaviani A; Spagnoli GC
Life Sci Alliance; 2022 Dec; 5(12):. PubMed ID: 36241426
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.
Birts CN; Savva C; Laversin SA; Lefas A; Krishnan J; Schapira A; Ashton-Key M; Crispin M; Johnson PWM; Blaydes JP; Copson E; Cutress RI; Beers SA
Sci Rep; 2022 May; 12(1):7802. PubMed ID: 35610242
[TBL] [Abstract] [Full Text] [Related]
8. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes After breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.
Chapman BV; Liu D; Shen Y; Olamigoke OO; Lakomy DS; Barrera AMG; Stecklein SR; Sawakuchi GO; Bright SJ; Bedrosian I; Litton JK; Smith BD; Woodward WA; Perkins GH; Hoffman KE; Stauder MC; Strom EA; Arun BK; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):426-436. PubMed ID: 34610390
[TBL] [Abstract] [Full Text] [Related]
10. Homogeneously high expression of cd32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Wang G; Sun X; Zuo S; Li C; Niu Q; Xia Y; Meng Y; Liu M; Fang Z; Yang X; Jiang Y; Wang S; Cui H; Huang H; Jiang E; Zhou D; Deng Q; Pan J; Feng X
J Hematol Oncol; 2021 Sep; 14(1):149. PubMed ID: 34530888
[TBL] [Abstract] [Full Text] [Related]
11. Margetuximab: First Approval.
Markham A
Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
[TBL] [Abstract] [Full Text] [Related]
12. Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
Pauly N; Baert T; Schmutzler R; du Bois A; Schneider S; Rhiem K; Schömig-Markiefka B; Siemanowski J; Heikaus S; Traut A; Heitz F; Prader S; Ehmann S; Harter P; Ataseven B
Arch Gynecol Obstet; 2021 Oct; 304(4):975-984. PubMed ID: 33710393
[TBL] [Abstract] [Full Text] [Related]
13. Temporal trends in age at menarche and age at menopause: a population study of 312 656 women in Norway.
Gottschalk MS; Eskild A; Hofvind S; Gran JM; Bjelland EK
Hum Reprod; 2020 Feb; 35(2):464-471. PubMed ID: 31990353
[TBL] [Abstract] [Full Text] [Related]
14. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by cd32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Pastore D; Cenciarelli C; Venditti A; Del Principe MI; Lauro D; Landoni E; Du H; Savoldo B; Ferrone S; Dotti G; Sconocchia G
Int J Cancer; 2020 Jan; 146(1):236-247. PubMed ID: 31479522
[TBL] [Abstract] [Full Text] [Related]
15. Screening Mammography Findings From One Standard Projection Only in the Era of Full-Field Digital Mammography and Digital breast Tomosynthesis.
Cohen EO; Tso HH; Phalak KA; Mayo RC; Leung JWT
AJR Am J Roentgenol; 2018 Aug; 211(2):445-451. PubMed ID: 29792742
[TBL] [Abstract] [Full Text] [Related]
16. iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.
Qing X; Chinenov Y; Redecha P; Madaio M; Roelofs JJ; Farber G; Issuree PD; Donlin L; Mcllwain DR; Mak TW; Blobel CP; Salmon JE
J Clin Invest; 2018 Apr; 128(4):1397-1412. PubMed ID: 29369823
[TBL] [Abstract] [Full Text] [Related]
17. Risks of breast, Ovarian, and Contralateral breast cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract] [Full Text] [Related]
18. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic breast cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract] [Full Text] [Related]
19. Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.
Hertz DL; Rae JM
Clin Cancer Res; 2016 Jul; 22(13):3121-3. PubMed ID: 27012810
[TBL] [Abstract] [Full Text] [Related]
20. Mitochondrial Reprogramming Regulates breast cancer Progression.
Kannan A; Wells RB; Sivakumar S; Komatsu S; Singh KP; Samten B; Philley JV; Sauter ER; Ikebe M; Idell S; Gupta S; Dasgupta S
Clin Cancer Res; 2016 Jul; 22(13):3348-60. PubMed ID: 26888829
[TBL] [Abstract] [Full Text] [Related]
[Next]
